Natalizumab (Tysabri®) SC

Reduce direct handling to a minimum and wear appropriate personal protective equipment
Check which form before administering – SC or IV

CAUTION: High Administration Risk Rating

Form & Storage	150 mg solution for injection in pre-filled syringe for sub-cut administration	Refrigerate at 2°C - 8°C and protect from light.
Reconstitution	Already in Solution	
Compatibility & Stability	N/A	
Administration	**SC injection** • The recommended dose for subcutaneous administration is 300 mg every 4 weeks. As each pre-filled syringe contains 150 mg natalizumab two pre-filled syringes need to be administered to the patient. • The sites for subcutaneous injection are the thigh, abdomen, or the posterior aspect of the upper arm. The injection should not be made into an area of the body where the skin is irritated, reddened, bruised, infected, or scarred in any way. • When removing the syringe from the injection site, the plunger should be let go of while pulling the needle straight out. Letting go of the plunger will allow the needle guard to cover the needle. • The second injection should be more than 3 cm away from the first injection location	
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.	
Adverse Drug Reactions	Medicinal products for the treatment of hypersensitivity reactions, e.g. adrenaline, oxygen, antihistamines and corticosteroids should be available for immediate use in the event of an allergic reaction during administration of all infusions.	
Monitoring	• If the patient meets the criteria in section **7.7*,** medical review may be is required prior to administration • Natalizumab naïve patients should be observed during the injection and for 1 hour after for signs and symptoms of injection reactions including hypersensitivity for the first 6 natalizumab doses. • For patients currently receiving natalizumab and who have already received at least 6 doses, regardless of the route of natalizumab administration used for the first 6 doses, the 1-hour post-injection observation time for subsequent subcutaneous injections may be reduced or removed according to clinical judgement if the patients have not experienced any injection/infusion reactions. • Pre and post infusion vital signs • JCV testing is required every 6 months • Urinalysis is required only if patient is symptomatic • Neurological assessment by Neurology CNS if patient is symptomatic • Annual MRI	
Disposal	Any unused medicinal product or waste material should be disposed of in a purple bin.	

Additional Information	• *See **PPG-CUH-CUH-243** Policy Procedure and Guidelines for management of patients attending CUH infusion unit for intravenous therapy for different administration protocols. • Patient Alert Card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). • Any switch in route of administration of the medicinal product should be made 4 weeks after the previous dose.

Information provided relates to Tysabri® (Biogen)